Unravelling Strategies across
Cardiorenal Management with SGLT2i
6 May 2026
Dr Chan Pak Hei 陳栢羲 Michael
MBBS (HK) · MD (HK) · MPCP (UK) · FRCP (Lond) · FRCP (Edin) · FRCP (Glasg) · FHKCP · FHKAM (Medicine)
Abstract
Cardiovascular, kidney, and metabolic (CKM) health are tightly interconnected; chronic kidney disease (CKD) amplifies cardiovascular and heart failure (HF) risk, while HF accelerates kidney decline. Risk assessment is evolving beyond traditional atherosclerotic models, with tools like the PREVENT equation integrating CKM domains. Early detection using dual assessment of kidney function and damage—eGFR and urine albumin–creatinine ratio (UACR)—is critical, as albuminuria often precedes eGFR decline.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) deliver organ protection beyond glycaemia across diabetes status. Latest publications suggest SGLT2is reduce sustained eGFR decline, end-stage kidney disease, and renal death in CKD with increasing evidence in lower uACR use. SGLT2is also reduce cardiovascular death or HF hospitalization and rapidly improve symptoms and health status across LVEF in Heart Failure patients.
Dr Chan Pak Hei 陳栢羲 Michael
MBBS (HK) · MD (HK) · MPCP (UK) · FRCP (Lond) · FRCP (Edin) · FRCP (Glasg) · FHKCP · FHKAM (Medicine)
Dr. Chan is an Honorary Clinical Associate Professor at the University of Hong Kong, where he also obtained his MBBS and MD degrees.He received fellowships from the American College of Cardiology and the Royal Colleges of Physicians in London, Edinburgh, and Glasgow.